Henry Gosebruch, Neumora CEO
With IPO money, Neumora eyes deals as CEO brings M&A chops from roles at AbbVie, JP Morgan
Neumora Therapeutics, a brain disease biotech born out of stitching together multiple neuroscience startups, is looking to replicate its original playbook by complementing its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
